AzTrials
AzTrials

StrokeNCT03176420

Endovascular Revascularization of Symptomatic Chronically Occluded Internal Carotid Artery

A study testing angioplasty and stenting of occluded cervical ICA in people with Stroke and Occlusion Carotid, run by University of Iowa.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This is a phase 2 randomized single-center open label clinical trial with randomization of 1:1 to either best medical management vs. best medical management and endovascular revascularization of chronically occluded ICA (COICA). Read more about this study

Who is it for?
Ages 21 to 90 years
Conditions the study is for
Stroke, Occlusion Carotid
What is being tested?
angioplasty and stenting of occluded cervical ICA
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
No sites listed yet
Study dates
1 Mar 2020to 31 Mar 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 21
  • Complete occlusion of cervical ICA on imaging studies (MRA or CTA) and confirmed with DSA
  • History of TIA or stroke within 120 days of enrollment
  • increased MTT on CTP in the ipsilateral side of the occluded ICA specifically in the MCA territory when compared to the opposite unaffected hemisphere
  • All occlusion is due to atherosclerotic disease
  • MoCA < 26 but ≥23

Who cannot join

  • History of Moyamoya or Moyamoya like disease
  • Tandem occlusion
  • No evidence of increased MTT on CT perfusion
  • Severe co-morbid diseases: end-stage renal disease, liver cirrhosis, COPD requiring home oxygen, terminal illness such as cancer, Parkinson disease or other neurodegenerative diseases, severe cognitive heart failure, seizures, debilitating stroke, mRS ≥3.
  • Short life expectancy due to cancer or other co-morbid diseases
  • Class D on COICA classification

About this study

Official title: The Safety and Feasibility of Endovascular Revascularization of Chronically Occluded Cervical Internal Carotid Artery (COICA) Using Newly Suggested Radiographic Classification of COICA: Pilot Study

This is a phase 2 randomized single-center open label clinical trial with randomization of 1:1 to either best medical management vs. best medical management and endovascular revascularization of chronically occluded ICA (COICA). The study will utilize best medical management and will randomize patients to endovascular balloon angioplasty and stenting.

Primary Objective:

Read more

To test the hypothesis that endovascular revascularization of COICA improves significantly cognitive function assessed by a specifically designed battery of 14 cognitive tests including the Montreal Cognitive Assessment (MoCA).

Secondary Objective:

To test the safety of endovascular revascularization of chronically occluded ICA.

Tertiary/exploratory Objectives:

To test the hypothesis that subjects with symptomatic COICAs and mild/moderate cognitive dysfunction have the following biomarkers:

  1. Presence of lactate and decreased Naa/Cr in the watershed area (specifically centrum semiovale) on 1H-MRI-spectroscopy, and B) Decreased size of the hippocampus and amygdala on MRI. C) increased MTT on CTP in the ipsilateral side of the occluded ICA specifically in the MCA territory when compared to the opposite unaffected hemisphere.
Read the detailed description

Background:

Complete occlusion of the internal carotid artery (COICA) by atherosclerotic disease causes approximately 15%-25% of ischemic strokes in the carotid artery distribution. Patients treated with medical therapy have 5%-8% risk per year for ipsilateral ischemic stroke during the first 2 years after internal carotid artery occlusion. Internal carotid artery occlusion causes an estimated 61,000 first-ever strokes per year in the USA, an incidence more than twice the annual occurrence of ruptured intracranial aneurysms. Additionally, 40% of subjects with COICA who present with transient ischemic attacks (TIA) and 70% of COICA who present with stroke have cognitive decline with significantly increased risk of vascular dementia and Alzheimer's' disease (AD) with time 2,3.

Our group and others have used an alternative approach to revascularize subjects with COICAs. These studies showed the feasibility and safety of using endovascular angioplasty and stenting (EAS) and/or hybrid of both carotid endarterectomy (CEA) and EAS to restore cerebral flow to the ipsilateral hemisphere of the COICA. A meta-analysis of these studies, identified 333 subjects with COICA, an average age of 67.2 ± 9.3 years, and a male proportion of 85%. The average known occlusion time was 8.8 ± 10.0 months. Successful revascularization was achieved in 70% (232/333), with major complications found in 13 (3.9%) subjects and minor complications in 8 (2.4%) subjects. Furthermore, our group devised a new angiographic and anatomic classification to upfront predict the success of revascularization using these techniques. This classification was tested in 2 pilot studies and the results showed robust plausibility to predict upfront the percentage of success anticipated in revascularizing these lesions using these techniques. In addition, 3 groups including ours showed that revascularization using these techniques restored cerebral blood flow to the ipsilateral hemisphere of the COICA evident of normalization of mean transient time (MTT) on CT perfusion (CTP) and significant improvement in the cognitive function. Previous attempts to improve cognitive function in this cohort failed using bypass (COSS Trial).The rationale for failure is the fact that this technique relied on a very small caliber donor artery (STA) to revascularize the entire hemisphere affected. This significantly improved the oxygen extraction in the middle cerebral artery territory affected but failed to normalize it. Additionally, this technique provided cerebral flow to majority of ipsilateral middle cerberal artery territory but not enough to vascularize the Anterior cerebral artery territory, which supplies the majority of the limbic system involved in executive and cognitive functioning. EAS and hybrid technique restore the caliber of the cervical internal carotid arteryand therefore, the blood flow to all involved vessels (anterior and middle cerebral artery, and other branches) with clear evidence of complete resolution of penumbra and normalization of MTT on CTP. This could provide an explanation of the difference of both techniques in improving cognitive function.

All subjects who presents to our tertiary hospital with a diagnosis of COICA will undergo full evaluation including 1) documenting previous history of TIA and/or stroke; 2) cervical and brain CTA to document complete occlusion; 3) CTP to assess for presence of penumbra evident by increased MTT in the ipsilateral side of COICA; and 4) MoCA. If any subject is found to have complete occlusion of COICA, evident of abnormal/prolongation of MTT on CTP, previous history of TIA and or stroke, and MoCA <26 \& ≥ 23, then further evaluation is obtained including: 1H-MRI spectroscopy to assess for presence/absence of lactate in the ipsilateral watershed area (centrum semiovale), ratio of Naa/Cr, and size of ipsilateral hippocampus and amygdala, additional cognitive testing battery, and DSA to document adequately the type of COICA the subject have (type A-D).

If any subject does not have complete occlusion, or complete occlusion but no abnormalities on CTP and/or MoCA >26, then the subject is excluded and no further testing needed (see exclusion criteria).

If the subject meets all inclusion criteria, then a baseline of complete neurological testing, full demographics, CTA or MRA, CTP, MoCA, additional neurological testing (see below), 1H-MRI sectroscopy and DSA are obtained and subject is randomized 1:1 to either best medical management or best medical management + endovascular balloon angioplasty and stenting. Follow up clinic visits are arranged at 3 and 12 months. Repeat testing of MoCA and additional cognitive testing battery are done at these clinical follow-up visits (3 and 12 months). MRI of the brain and DSA is performed at 1 year follow-up to assess brain biomarkers and revascularization respectively.

Being tested
angioplasty and stenting of occluded cervical ICA
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • angioplasty and stenting of occluded cervical ICAProcedure or surgery

    The procedure is performed under monitored anesthetic care. We will perform a thorough and complete six-vessel diagnostic angiogram to completely characterize the occlusion and presence of collaterals. A distal protection device is used unless technically can't be delivered beyond the occlusion or when the occlusion extends beyond the petrous segment of the internal carotid artery. Balloon angioplasty is performed followed by deployment of covered stents to jail the clot/organized thrombus. The carotid reconstruction is performed from the distal to the proximal segment with coronary stents that are telescoped until normal flow is encounter. The Blood pressure is managed rigorously during and after the procedure to minimize the chances of reperfusion hemorrhage.

Study groups in NCT03176420
Study groupRoleWhat they receive
Interventional armExperimentalEndovascular treatment of occluded carotids
Receives: Procedure: angioplasty and stenting of occluded cervical ICA
medical armNo interventionmaximal medical therapy of occluded carotids

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Endovascular revascularization that improves cognitive outcome

    This is one outcome that reflects the overall cognition. The composite cognitive score at 12-month follow-up is assessed by a composite z score based on the average z score for the tests for each subject (sum of the z scores divided by the number of tests included) from a specifically designed battery of 14 cognitive tests. Scores from tests in the proposed neuropsychological battery will be converted to z-scores. This is the following battery:

    Montreal Cognitive Assessment (MoCA),Wide Range Achievement Test-5 (WRAT-5); Wechsler Adult Intelligence Scale - IV (WAIS-IV); WAIS-IV, Coding subtest; WAIS-IV, Matrix Reasoning subtest; Hopkins Verbal Learning Test ; Benton Visual Retention Test (BVRT) ; Controlled Oral Word Association (COWA) Test; Boston Naming Test;Boston Diagnostic Aphasia Examination, Complex Ideational Material subtest;Trail-Making Test, part A and part B; Beck Depression Inventory-Fast Screen (BDI-FS);Iowa Scales of Personality Change (ISPC).

    Measured: 12-month

Secondary outcomes (1)
  1. safety of the procedure

    Occurrence of Stroke, Cerebral Hemorrhage, or Death

    Measured: 12-month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jun 2017
  2. Study start1 Mar 2020 (estimated)
  3. Primary completion31 Mar 2022 (estimated)
  4. Study completion31 Mar 2023 (estimated)

Why it stopped: Study is not funded, PI has left the institution

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
1:1 randomization to maximal medical therapy vs endovascular intervention
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03176420
Sponsor's protocol ID
UIHC
Status last verified
May 2023
First submitted
30 May 2017
Last updated
30 May 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: After 1 year following completion of the study, data finalization will occur, and the final dataset will be available for access and distribution. The final dataset will be stripped of identifiers prior to release for sharing.disclosure We will make the data and associated documentation available to users only under a data sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.

Questions about this trial

What is this clinical trial studying?

A study testing angioplasty and stenting of occluded cervical ICA in people with Stroke and Occlusion Carotid, run by University of Iowa.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 30 May 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Endovascular revascularization that improves cognitive outcome (time frame: 12-month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in